PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

plazomicin Side Effects

The reactions most often reported to the FDA for plazomicin (also sold as Zemdri), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

3
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2021 to 2022. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of plazomicin come from 3 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 3 reports to the FDA Adverse Event Reporting System (FAERS) for plazomicin (Zemdri): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

3

Hospitalizations

1

33.3% of reports

Top Indication

Infusion

Most Reported Adverse Reactions

ACUTE KIDNEY INJURY
1
ANTIBIOTIC LEVEL ABOVE THERAPEUTIC
1
CREATININE RENAL CLEARANCE DECREASED
1
DRUG EFFECT LESS THAN EXPECTED
1
GASTROINTESTINAL HAEMORRHAGE
1
RENAL FAILURE
1

Who Reports Side Effects

Gender Distribution

Male 2 (100%)

Age Distribution

18-44 1 (100%)

Reporting Trend by Year

21
22

Reactions in Hospitalization Reports

Top reactions in 1 reports where hospitalization was an outcome.

Reaction Reports
CREATININE RENAL CLEARANCE DECREASED 1
RENAL FAILURE 1

Compare plazomicin vs amikacin →

What the FAERS Data Reveals About plazomicin Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 3 voluntary reports linked to plazomicin and its brand equivalents (Zemdri), spanning 2021 through 2022. No reports in this dataset listed death as an outcome and 1 (33.3%) involved hospitalization. The most common indication reported alongside adverse events was Infusion.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 0% were female and 100% male; age distribution skews toward 18-44, with 1 report in that bracket. The single most reported reaction is acute kidney injury with 1 submission, followed by antibiotic level above therapeutic and creatinine renal clearance decreased.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.

Drugs With a Similar FAERS Report Volume

Other medications with a total FDA adverse-event report count closest to plazomicin's 3.